Regorafenib
| CAS No. | 755037-03-7 |
|---|---|
| MDL No. | MFCD16038047 |
| MF | C21H15ClF4N4O3 |
| MW | 482.80 |
| InChI Key | FNHKPVJBJVTLMP-UHFFFAOYSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Regorafenib is a pyridinecarboxamide formed by the condensation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]pyridine-2-carboxylic acid with methylamine. It is used in the treatment of metastatic colorectal cancer in patients who have undergone prior chemotherapy, anti-EGFR, or anti-VEGF therapy. Regorafenib functions as an antineoplastic agent, tyrosine kinase inhibitor, and hepatotoxic agent. It is classified as an aromatic ether, pyridinecarboxamide, monochlorobenzenes, (trifluoromethyl)benzenes, monofluorobenzenes, and phenylurea.
| CAS No. | 755037-03-7 |
|---|---|
| Product Name | Regorafenib |
Biological Targets
DDR2·EPHA2·FGFR1·FGFR2·MAPK11·
Associated Conditions
grade III meningioma·malignant colon neoplasm·glioblastoma multiforme·liposarcoma·intrahepatic cholangiocarcinoma·
* The information provided here is compiled from public sources and is for reference only.
